Systematic review of amifostine for the management of oral mucositis in cancer patients

被引：97

作者：

Nicolatou-Galitis, Ourania ^{[1
]}

Sarri, Triantafyllia ^{[1
]}

Bowen, Joanne ^{[2
]}

Di Palma, Mario ^{[3
]}

Kouloulias, Vassilios E. ^{[4
]}

Niscola, Pasquale ^{[5
]}

Riesenbeck, Dorothea

Stokman, Monique ^{[6
]}

Tissing, Wim ^{[7
]}

Yeoh, Eric ^{[2
,8
]}

Elad, Sharon ^{[9
]}

Lalla, Rajesh V. ^{[10
,11
]}

机构：

[1] Univ Athens, Sch Dent, Clin Hosp Dent, Dent Oncol Unit, Athens, Greece

[2] Univ Adelaide, Sch Med Sci, Adelaide, SA, Australia

[3] Inst Gustave Roussy, Ambulatory Dept, Villejuif, France

[4] Attiko Hosp, Sch Med, Dept Radiol 2, Athens, Greece

[5] St Eugenio Hosp, Hematol Unit, Rome, Italy

[6] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, Groningen, Netherlands

[7] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Oncol, Groningen, Netherlands

[8] Royal Adelaide Hosp, Dept Radiat Oncol, Adelaide, SA 5000, Australia

[9] Univ Rochester, Med Ctr, Eastman Inst Oral Hlth, Div Oral Med, Rochester, NY 14642 USA

[10] Univ Connecticut, Ctr Hlth, Sect Oral Med, Farmington, CT USA

[11] Univ Connecticut, Ctr Hlth, Neag Comprehens Canc Ctr, Farmington, CT USA

来源：

SUPPORTIVE CARE IN CANCER | 2013年 / 21卷 / 01期

关键词：

Amifostine; Guidelines; Systematic review; Oral mucositis; CLINICAL-PRACTICE GUIDELINES; STEM-CELL TRANSPLANTATION; HIGH-DOSE MELPHALAN; PHASE-III TRIAL; NECK-CANCER; SUBCUTANEOUS AMIFOSTINE; RADIATION-THERAPY; RANDOMIZED-TRIAL; SELECTIVE CYTOPROTECTION; INTRAVENOUS AMIFOSTINE;

D O I：

10.1007/s00520-012-1613-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for the use of amifostine, in each cancer treatment setting was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, or no guideline possible. Thirty papers were reviewed for evidence on amifostine as an intervention for oral mucositis. No guideline was possible for amifostine in any cancer treatment setting due to inadequate and conflicting evidence. Review of the amifostine studies for the prevention and treatment of oral mucositis has found insufficient evidence to support its use in any cancer treatment setting for this purpose. Additional well-designed research is needed to clarify the role of amifostine as an intervention for oral mucositis.

引用

页码：357 / 364

页数：8

共 44 条

[1] Phase II Study of Tolerance and Efficacy of Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin, and Paclitaxel (Taxol) and Amifostine (Ethyol) in Head and Neck Squamous Cell Carcinomas - A-3 Protocol [J].

Abitbol, A ;

Abdel-Wahab, M ;

Harvey, M ;

Lewin, A ;

Troner, M ;

Hamilton-Nelson, K ;

Wu, JH ;

Markoe, A .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (05) :449-455

[2] A phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer [J].

Anne, Pramila Rani ;

Machtay, Mitchell ;

Rosenthal, David I. ;

Brizel, David M. ;

Morrison, William H. ;

Irwin, David H. ;

Chougule, Prakash B. ;

Estopinal, Noel C. ;

Berson, Anthony ;

Curran, Walter J., Jr. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02) :445-452

[3] Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer [J].

Antonadou, D ;

Pepelassi, M ;

Synodinou, M ;

Puglisi, M ;

Throuvalas, N .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (03) :739-747

[4] Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study [J].

Benesch, M ;

McDonald, GB ;

Schubert, M ;

Appelbaum, FR ;

Deeg, HJ .

BONE MARROW TRANSPLANTATION, 2003, 32 (11) :1071-1075

[5] Amifostine in the management of radiation-induced and chemo-induced mucositis [J].

Bensadoun, Rene-Jean ;

Schubert, Mark M. ;

Lalla, Rajesh V. ;

Keefe, Dorothy .

SUPPORTIVE CARE IN CANCER, 2006, 14 (06) :566-572

[6] A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma [J].

Bourhis, J ;

De Crevoisier, R ;

Abdulkarim, B ;

Deutsch, E ;

Lusinchi, A ;

Luboinski, B ;

Wibault, P ;

Eschwege, F .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (05) :1105-1108

[7] Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [J].

Brizel, DM ;

Wasserman, TH ;

Henke, M ;

Strnad, V ;

Rudat, V ;

Monnier, A ;

Eschwege, F ;

Zhang, J ;

Russell, L ;

Oster, W ;

Sauer, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3339-3345

[8] Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study [J].

Buentzel, J ;

Micke, O ;

Adamietz, IA ;

Monnier, A ;

Glatzel, M ;

De Vries, A .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (03) :684-691

[9] Radiochemotherapy with amifostine cytoprotection for head and neck cancer [J].

Buntzel, J ;

Schuth, J ;

Kuttner, K ;

Glatzel, M .

SUPPORTIVE CARE IN CANCER, 1998, 6 (02) :155-160

[10] Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer [J].

Buntzel, J ;

Kuttner, K ;

Frohlich, D ;

Glatzel, M .

ANNALS OF ONCOLOGY, 1998, 9 (05) :505-509

← 1 2 3 4 5 →